Last week, Pfizer and BioNTech said their experimental COVID-19 vaccine was 90% effective in early interim results. And yesterday, they announced that their mRNA-based vaccine candidate is 95% effective at preventing COVID-19. Dr. Reynold Panettieri Jr. of Robert Wood Johnson Medical School, New Brunswick, New Jersey, told Medscape Medical News, “This is a game-changer. The Pfizer data hit the critical number of patients, that was 170, and showed 95% success, which was stunning data.” The clinical trial was ethnically diverse and its results were consistent across all genders and age groups, with a 94% efficacy seen in participants above 65 years of age. To read the full story.
Recent Posts
- Scientists Discover Immune Cell Networks Driving Deadly Lung Disease.
- Special Type of Fat Tissue Could Help Maintain Exercise Capacity in Aging.
- Fruit Fly Research Led NJIT Scientists and Edison Teens to Better AI Habits on Supercomputers.
- Biologist Pabitra Sahoo and His Research Team Unlock Clues to Repairing Damaged Nerves.
- For Cancer Patients, Oncologists Often Have the Final Word.
Categories
- Community (2,190)
- Covid (983)
- CTO Events (6)
- News (2,796)
- Pilots (21)